Stem cell therapeutics - ExCellThera

Drug Profile

Stem cell therapeutics - ExCellThera

Alternative Names: ECT 001; ECT 002; ECT 003; ECT 005; ECT-100; UM 171; UM171 + UM092; UM171 + UM390

Latest Information Update: 11 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ExCellThera
  • Class Gene therapies; Stem cell therapies
  • Mechanism of Action CD34-antigen-stimulants; Stem cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia; Haematological malignancies
  • Preclinical Immunological disorders

Most Recent Events

  • 01 Dec 2017 ECT 001 is available for licensing as of 01 Dec 2017.
  • 01 Dec 2017 Preclinical trials in Immunological disorders in USA (Parenteral) (ExCellThera pipeline, December 2017)
  • 01 Dec 2017 ExCellThera announces intention to submit regulatory applications in 2023 (ExCellThera pipeline, December 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top